Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.

Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.

The founder of Insys Therapeutics Inc. became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller.

Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.

U.S. President Donald Trump touted progress in the fight against opioid abuse and promised to hold drugmakers accountable for their part in the crisis, a day after his administration brought its first related criminal charges against a major drug distributor and company executives.

Purdue Pharma LP fraudulently transferred funds to members of the wealthy Sackler family who control the OxyContin maker despite knowing the company faced major liabilities that had made it already insolvent, New York’s attorney general alleged.

OxyContin maker Purdue Pharma LP is exploring filing for bankruptcy to address potentially significant liabilities from roughly 2,000 lawsuits alleging the drug manufacturer contributed to the deadly opioid crisis sweeping the United States, people familiar with the matter said.

Forcing patients off opioid painkillers could sometimes do more harm than good, international medical experts warn in an open letter to health authorities.

An advisory panel to the U.S. Food and Drug Administration narrowly recommended prescribing the opioid overdose reversal drug naloxone along with addictive painkillers.

The U.S. Food and Drug Administration declined to approve an abuse-deterrent version of Mallinckrodt Plc’s opioid painkiller Roxicodone, saying some parts of the company’s application need further evaluation.